Nieuwe risicovoorspellingsbenaderingen voor de primaire preventie van hart- en vaatziekten in Italië: de CVRISK-IT-studie (CVRISK-IT) (CVRISK-IT)
Nieuwe risicovoorspellingsbenaderingen voor de primaire preventie van hart- en vaatziekten in Italië: de CVRISK-IT-studie
The CVRISK-IT study aims to evaluate the health benefit of measuring genetic and imaging risk information in men and women considered at 'low-to-moderate' or 'high' risk of developing cardiovascular diseases (CVD) in a randomized controlled trial in Italian primary care settings. Our primary objective is to answer a fundamental question in the prevention and prediction of CVD in Italy and globally: is there any benefit in including additional information (such as genetic and/or imaging data) in estimating risk, in conjunction with lifestyle advice and medical treatment for primary prevention of CVD?
As a key secondary objective of the CVRISK-IT study, the goal is to build a large bioresource with clinical information and biological samples to facilitate a new generation of discovery and translational research that will advance understanding of the genetic, molecular and behavioural determinants as well as mechanisms of multiple chronic diseases in the Italian population. By contributing to the Rete Cardiologica database and the BBDCARDIO biobank, the CVRISK-IT study will also serve as a cornerstone for future investigations into the development and testing of early diagnostic technologies and preventive (or 'personalised precision health') interventions for chronic diseases.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This multicenter, open randomized trial will investigate the effects of providing additional CVD risk information alongside personalised lifestyle advice and medical treatment in a primary prevention context across Italy. Healthy individuals aged 40 to 80 years, with no prior history of CVD or diabetes, will be recruited in two phases from the cohort of 17 participating IRCCS across Italy and affiliated enrolling centers. The population enrolled in this study consists of subjects who have never participated in other cardiovascular prevention studies of the Rete Cardiologica.
Phase 1 - Identification of the study population and development of the bioresource: various recruitment sources will be used, including institutions, primary care centres/services, government agencies, occupational health services, and volunteer organizations (e.g., blood donors). Participants will provide informed consent, a blood sample, and complete an electronic questionnaire. Approximately 30,000 individuals will be recruited and assessed using SCORE2/SCORE2-OP risk prediction models. Those identified as 'very high' risk will receive immediate medical treatment and will not proceed to phase 2.
Phase 2 - Randomization and novel risk prediction interventions: Participants identified as 'low-to-moderate' or 'high' CVD risk during phase 1 will be randomized, following a 2x2 factorial design into four groups within 1 week upon enrolment: a control group (no additional risk information), and three intervention groups (genetic, imaging-based and genetic + imaging-based risk information). The goal is to randomize around 12,000 participants in phase 2 (~3,000 per trial arm). All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The remaining 18,000 participants who won't proceed to phase 2 will still be involved in the study and contacted through a phone call follow-up with specialist at the 5◦ and 10◦ year.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Ancona, Italië
- Werving
- Irccs Inrca
-
Contact:
- Roberto Antonicelli, MD
- Telefoonnummer: +390718003450
- E-mail: r.antonicelli@inrca.it
-
Genova, Italië
- Nog niet aan het werven
- IRCCS San Martino
-
Contact:
- Pietro Ameri, MD
- E-mail: pietro.ameri@unige.it
-
Milan, Italië
- Werving
- IRCCS Ospedale San Raffaele
-
Contact:
- Paolo Camici, MD
- Telefoonnummer: 02 2643 8190/8191
- E-mail: cvriskit@hsr.it
-
Milan, Italië
- Werving
- IRCCS Auxologico Italiano
-
Contact:
- Gianfranco Parati, MD
- Telefoonnummer: 02-61911.1
- E-mail: gianfranco.parati@unimib.it
-
Milan, Italië
- Werving
- IRCCS Cardiologico Monzino
-
Contact:
- Damiano Baldassarre, MD
- Telefoonnummer: +39 02.58002369
- E-mail: damiano.baldassarre@cardiologicomonzino.it
-
Milan, Italië
- Nog niet aan het werven
- IRCCS Fondazione Cà Granda- Policlinico Milano
-
Contact:
- Stefano Carugo, MD
- E-mail: stefano.carugo@policlinico.mi.it
-
Milan, Italië
- Nog niet aan het werven
- IRCCS Istituto Clinico Humanitas
-
Contact:
- Giuseppe Ferrante, MD
- E-mail: giuseppe.ferrante@hunimed.eu
-
Milan, Italië
- Werving
- IRCCS Mario Negri
-
Contact:
- Maria Carla Roncaglioni, MD
- Telefoonnummer: 0239014-501
- E-mail: cvrisk-it_fase1@marionegri.it
-
Milan, Italië
- Werving
- IRCCS Multimedica
-
Contact:
- Francesco Bandera, MD
- Telefoonnummer: 02.242091
- E-mail: francesco.bandera@multimedica.it
-
Naples, Italië
- Nog niet aan het werven
- Irccs Synlab Sdn
-
Contact:
- Carlo Cavaliere, MD
- E-mail: carlo.cavaliere@synlab.it
-
Palermo, Italië
- Nog niet aan het werven
- Irccs Ismett
-
Contact:
- Manlio Cipriani, MD
- E-mail: mcipriani@ismett.edu
-
Pavia, Italië
- Nog niet aan het werven
- IRCCS Istituti Clinici Scientifici Maugeri
-
Contact:
- Maria Teresa La Rovere, MD
- E-mail: mariateresa.larovere@icsmaugeri.it
-
Pavia, Italië
- Nog niet aan het werven
- IRCCS Fondazione Policlinico San Matteo
-
Contact:
- Eloisa Arbustini, MD
- E-mail: e.arbustini@smatteo.pv.it
-
Pozzilli, Italië
- Nog niet aan het werven
- IRCCS Neuromed
-
Contact:
- Maria Benedetta Donati, MD
- E-mail: mariabenedetta.donati@neuromed.it
-
Rome, Italië
- Nog niet aan het werven
- IRCCS Fondazione Policlinico Gemelli
-
Contact:
- Giovanna Liuzzo, MD
- E-mail: giovanna.liuzzo@policlinicogemelli.it
-
Rome, Italië
- Nog niet aan het werven
- IRCCS San Raffaele Roma
-
Contact:
- Massimo Volpe, MD
- E-mail: massimo.volpe@sanraffaele.it
-
San Donato Milanese, Italië
- Werving
- IRCCS Policlinico San Donato
-
Contact:
- Chiara Barberio, PhD
- Telefoonnummer: 02-52774838
- E-mail: cvriskit@grupposandonato.it
-
Contact:
- Ambra Cerri, PhD
-
Hoofdonderzoeker:
- Lorenzo Menicanti, MD
-
Onderonderzoeker:
- Emanuele Diangelantonio, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age: 40-80 years
- Apparently healthy individuals without previous medical history of CVD or diabetes (based on medical diagnosis)
- Participant recruitment arranged only at selected IRCCS (and associated Spokes) as part of the 'Rete Cardiologica'
- Participants must have signed the Informed Consent and Data Privacy Treatment forms
- Participants must have a personal e-mail address and internet connection
Exclusion Criteria:
- Age ≤40 or ≥80 years
- Individuals have previous medical history related to CVD (e.g., heart failure, congenital heart disorder, coronary heart disease) based on medical diagnosis
- Candidates have previously participated in clinical studies of 'Rete Cardiologica' (e.g., PREVITAL)
- Medical diagnosis of mental disorders
- Pregnancy based on self-reported information
- Previous history of type 1 or type 2 diabetes (based on medical diagnosis)
- Oncology patients (based on physician indication)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Faculteitstoewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Control
No additional cardiovascular risk information/recommendation is provided to the subject other than SCORE2/SCORE2-OP results of phase I. Thereby, the control group does not undergo neither imaging nor genetic analysis. |
|
|
Experimenteel: Imaging
Subjects randomized in the imaging arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on imaging data analysis (i.e., carotid ultrasound or calcium score) |
All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I. |
|
Experimenteel: Polygenic Risk Score (PRS)
Subjects randomized in this arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on polygenic risk score (PRS) analysis obtained from blood samples collected at the baseline visit |
All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I. |
|
Experimenteel: Imaging and Polygenic Risk Score (PRS)
Subjects randomized in this arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on both imaging data (e.g., carotid ultrasound and/or calcium score) and genetic analysis (e.g., PRS). |
All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in CVD risk using SCORE2/SCORE2-OP
Tijdsspanne: 12 months
|
The primary short-term outcome (i.e., 12 months after communication of the newly estimated CVD risk, following the randomisation step) is the change in CVD risk measured using SCORE2/SCORE2-OP risk prediction models. The CVD risk categories used to classify healthy people according to these scores are: 1) Low-to-moderate CVD risk: <50 years = <2.5 %; 50-69 years = <5%; ≥ 70 years = <7.5%. High CVD risk: <50 years = 2.5 to <7.5%; 50-69 years = 5 to <10%; ≥ 70 years 7.5 to <15%; Very high CVD risk: <50 years = ≥7.5%; 50-69 years = ≥10%; ≥ 70 years = ≥ 15%. |
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in cardiovascular modifiable risk factors
Tijdsspanne: 12 months
|
Secondary short-term outcomes will include changes in objectively measured risk factors, such as cholesterol levels (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) (mg/dl) |
12 months
|
|
Change in cardiovascular modifiable risk factors
Tijdsspanne: 12 months
|
Secondary short-term outcomes will include changes in objectively measured risk factors, such as blood pressure which will be measured 3 times in a row, and its average calculated (mmHg) |
12 months
|
|
Change in cardiovascular modifiable risk factors
Tijdsspanne: 12 months
|
Secondary short-term outcomes will include changes in objectively measured risk factors, such as smoking habits (e.g., switch from "usual smoker" to "not smoking anymore" categories) |
12 months
|
|
Change in CVD prevention-drugs prescription
Tijdsspanne: 12 months
|
Secondary short-term outcomes will include changes in CVD prevention-drugs prescription with respect to the baseline visit |
12 months
|
|
Evaluation of participant's adherence to ESC recommendations
Tijdsspanne: 12 months
|
By means of validated questionnaires, the assessment of participants' adherence to the lifestyle and dietary guidelines of the European Society of Cardiology (ESC) will be performed. If and where applicable, drugs prescription adherence will be evaluated as well as psychological outcomes |
12 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
CVD events recording in long-term period
Tijdsspanne: 5-10 years
|
The long-term outcomes will include the registration of CVD events in all enrolled participants in the long-term period (e.g., non-fatal myocardial infarction, acute coronary syndrome, percutaneous transluminal coronary angioplasty (PTCA), Coronary artery bypass grafting (CABG), non-fatal stroke), CVD mortality, and total mortality |
5-10 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Publicaties en nuttige links
Algemene publicaties
- Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, Kazakiewicz D, de Benito Rubio V, Ignatiuk B, Raisi-Estabragh Z, Pawlak A, Karagiannidis E, Treskes R, Gaita D, Beltrame JF, McConnachie A, Bardinet I, Graham I, Flather M, Elliott P, Mossialos EA, Weidinger F, Achenbach S; Atlas Writing Group, European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022 Feb 22;43(8):716-799. doi: 10.1093/eurheartj/ehab892.
- Di Angelantonio E, Piepoli M, Castelvecchio S, Barberio C, Chiarello C, Cerri A, Boveri S, Cardani R, Ambrogi F, Guelfi S, Baldassarre D, Colombo G, Amato M, Baetta R, Arbustini E, Liuzzo G, Kaptoge S, Severino A, Ferrante G, La Rovere MT, Parati G, Pengo MF, Latini R, Roncaglioni MC, Rigoni M, De Curtis A, Frati L, Ameri P, Camici PG, Volpe M, Menicanti L. Integrating genetic and imaging information to enhance cardiovascular risk stratification: rationale and design of the CVRISK-IT randomised controlled trial. Eur Heart J Qual Care Clin Outcomes. 2026 Mar 4:qcag032. doi: 10.1093/ehjqcco/qcag032. Online ahead of print.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- CVRISK-IT
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .